{"title":"一站式68Ga-FAPI/18F-FDG全身PET/CT扫描：提供更多治疗学信息。","authors":"Huaping Gao, Han Tang, Zhe Zheng, Haojun Yu, Wujian Mao, Yu Lin, Jiefu Zheng, Akram Al-Ibraheem, Yibo He, Wenxin Tang, Runjun Yang, Yunze Xie, Lijie Tan, Hongcheng Shi","doi":"10.1097/RLU.0000000000005673","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging.</p><p><strong>Patients and methods: </strong>Forty patients underwent one-stop 68 Ga-FAPI-04 PET (PET FAPI ) and dual-radiotracer PET (PET DUAL ) using a total-body PET/CT scanner with a 194-cm axial field of view. After a half-dose (0.925 MBq/kg) 68 Ga-FAPI-04 PET/CT, an additional half-dose (1.85 MBq/kg) of 18 F-FDG was administered for a 60-minute dynamic acquisition. PET DUAL was reconstructed at 10-minute intervals (PET D0-10 , PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 ). Data of lesion detectability, target-to-background ratios, tumor staging, and total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on PET FAPI was considered indicative of sufficient fibroblast activation protein expression.</p><p><strong>Results: </strong>PET D50-60 and PET FAPI showed similar performance in detecting primary tumors (42 vs 41, P > 0.999). However, significantly more metastatic lesions were identified on PET D50-60 compared with PET FAPI (102 vs 60, P < 0.001). PET FAPI demonstrated significantly higher TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio than PET DUAL ( P < 0.05). Lesion detectability was similar across PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 (all P 's > 0.05). Notably, PET D30-40 and PET D40-50 detected all lesions identified by PET D50-60 . PET D40-50 showed no significant differences in TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio compared with PET D50-60 ( P > 0.05). Up to 94.9% of malignant primary lesions exhibited a TLR ≥ 3 on PET FAPI . The average effective dose was 9.85 ± 2.19 mSv, similar to that of a whole-body 18 F-FDG PET/CT.</p><p><strong>Conclusions: </strong>This one-stop, dual-radiotracer, dual-low-activity imaging protocol combines the strengths of 68 Ga-FAPI-04 and 18 F-FDG, offering a shorter imaging duration and reduced radiation exposure.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e253-e261"},"PeriodicalIF":9.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"One-Stop 68 Ga-FAPI/ 18 F-FDG Total-Body PET/CT Scan : More Theranostics Information Available.\",\"authors\":\"Huaping Gao, Han Tang, Zhe Zheng, Haojun Yu, Wujian Mao, Yu Lin, Jiefu Zheng, Akram Al-Ibraheem, Yibo He, Wenxin Tang, Runjun Yang, Yunze Xie, Lijie Tan, Hongcheng Shi\",\"doi\":\"10.1097/RLU.0000000000005673\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging.</p><p><strong>Patients and methods: </strong>Forty patients underwent one-stop 68 Ga-FAPI-04 PET (PET FAPI ) and dual-radiotracer PET (PET DUAL ) using a total-body PET/CT scanner with a 194-cm axial field of view. After a half-dose (0.925 MBq/kg) 68 Ga-FAPI-04 PET/CT, an additional half-dose (1.85 MBq/kg) of 18 F-FDG was administered for a 60-minute dynamic acquisition. PET DUAL was reconstructed at 10-minute intervals (PET D0-10 , PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 ). Data of lesion detectability, target-to-background ratios, tumor staging, and total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on PET FAPI was considered indicative of sufficient fibroblast activation protein expression.</p><p><strong>Results: </strong>PET D50-60 and PET FAPI showed similar performance in detecting primary tumors (42 vs 41, P > 0.999). However, significantly more metastatic lesions were identified on PET D50-60 compared with PET FAPI (102 vs 60, P < 0.001). PET FAPI demonstrated significantly higher TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio than PET DUAL ( P < 0.05). Lesion detectability was similar across PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 (all P 's > 0.05). Notably, PET D30-40 and PET D40-50 detected all lesions identified by PET D50-60 . PET D40-50 showed no significant differences in TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio compared with PET D50-60 ( P > 0.05). Up to 94.9% of malignant primary lesions exhibited a TLR ≥ 3 on PET FAPI . The average effective dose was 9.85 ± 2.19 mSv, similar to that of a whole-body 18 F-FDG PET/CT.</p><p><strong>Conclusions: </strong>This one-stop, dual-radiotracer, dual-low-activity imaging protocol combines the strengths of 68 Ga-FAPI-04 and 18 F-FDG, offering a shorter imaging duration and reduced radiation exposure.</p>\",\"PeriodicalId\":10692,\"journal\":{\"name\":\"Clinical Nuclear Medicine\",\"volume\":\" \",\"pages\":\"e253-e261\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/RLU.0000000000005673\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005673","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的：本前瞻性研究旨在评估68Ga-FAPI-04/18F-FDG双低活性双示踪剂一站式肿瘤成像方案的可行性。患者和方法：40例患者使用194 cm轴向视野的全身PET/CT扫描仪进行一站式68Ga-FAPI-04 PET （PETFAPI）和双放射性示踪PET （PETDUAL）。在给予半剂量（0.925 MBq/kg）的68Ga-FAPI-04 PET/CT后，再给予半剂量（1.85 MBq/kg）的18F-FDG进行60分钟的动态采集。PETDUAL每隔10分钟重建一次（PETD0-10、PETD10-20、PETD20-30、PETD30-40、PETD40-50和PETD50-60）。分析病灶可检出性、靶本比、肿瘤分期和总辐射剂量等数据。PETFAPI靶肝比(TLR)≥3被认为表明成纤维细胞活化蛋白表达充足。结果：PETD50-60与PETFAPI对原发肿瘤的检测效果相近（42 vs 41, P < 0.05 0.999）。然而，与PETFAPI相比，PETD50-60发现的转移性病变明显更多（102 vs 60, P 0.05）。值得注意的是，PETD30-40和PETD40-50可以检测到PETD50-60所识别的所有病变。PETD40-50与PETD50-60相比，TLR、靶与血池比值、靶与正常组织比值无显著差异（P < 0.05）。高达94.9%的恶性原发病变在PETFAPI上表现为TLR≥3。平均有效剂量为9.85±2.19 mSv，与18F-FDG全身PET/CT相似。结论：这种一站式、双放射性示踪剂、双低活度成像方案结合了68Ga-FAPI-04和18F-FDG的优势，提供了更短的成像时间和更少的辐射暴露。
One-Stop 68 Ga-FAPI/ 18 F-FDG Total-Body PET/CT Scan : More Theranostics Information Available.
Purpose: This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging.
Patients and methods: Forty patients underwent one-stop 68 Ga-FAPI-04 PET (PET FAPI ) and dual-radiotracer PET (PET DUAL ) using a total-body PET/CT scanner with a 194-cm axial field of view. After a half-dose (0.925 MBq/kg) 68 Ga-FAPI-04 PET/CT, an additional half-dose (1.85 MBq/kg) of 18 F-FDG was administered for a 60-minute dynamic acquisition. PET DUAL was reconstructed at 10-minute intervals (PET D0-10 , PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 ). Data of lesion detectability, target-to-background ratios, tumor staging, and total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on PET FAPI was considered indicative of sufficient fibroblast activation protein expression.
Results: PET D50-60 and PET FAPI showed similar performance in detecting primary tumors (42 vs 41, P > 0.999). However, significantly more metastatic lesions were identified on PET D50-60 compared with PET FAPI (102 vs 60, P < 0.001). PET FAPI demonstrated significantly higher TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio than PET DUAL ( P < 0.05). Lesion detectability was similar across PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 (all P 's > 0.05). Notably, PET D30-40 and PET D40-50 detected all lesions identified by PET D50-60 . PET D40-50 showed no significant differences in TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio compared with PET D50-60 ( P > 0.05). Up to 94.9% of malignant primary lesions exhibited a TLR ≥ 3 on PET FAPI . The average effective dose was 9.85 ± 2.19 mSv, similar to that of a whole-body 18 F-FDG PET/CT.
Conclusions: This one-stop, dual-radiotracer, dual-low-activity imaging protocol combines the strengths of 68 Ga-FAPI-04 and 18 F-FDG, offering a shorter imaging duration and reduced radiation exposure.
期刊介绍：
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
